What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What critical advances in the development of long-acting insulin and GLP-1 RA—and combination approaches using both—are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA? And how should we align specific drugs with specific patients?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stefano Del Prato, MD PhD

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
University of Pisa, Italy
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, Texas